



## ASX Announcement

21 March 2025

### Upcoming Release of Shares from Escrow

**Sydney, Australia; 21 March 2025:** Cambium Bio Limited (ASX:CMB) (**Cambium Bio, or Company**) today announces, pursuant to ASX Listing Rule 3.10A, that 2,468,094 fully paid ordinary shares (Shares) will be released from voluntary escrow on 5 April 2025. The escrow arrangements are in connection with the merger with Cambium Medical Technologies, LLC on 5 April 2024.

- ENDS -

#### About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit [www.cambium.bio](http://www.cambium.bio)

#### Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung  
Corporate Secretary  
[info@cambium.bio](mailto:info@cambium.bio)  
1 300 995 098